Literature DB >> 30070016

Asymmetric synthesis of tetrahydroquinoline-type ecdysone agonists and QSAR for their binding affinity against Aedes albopictus ecdysone receptors.

Taiyo Yokoi1, Yoshiaki Nakagawa1, Hisashi Miyagawa1.   

Abstract

BACKGROUND: Tetrahydroquinolines (THQs) are a class of non-steroidal ecdysone agonists that specifically bind to mosquito ecdysone receptors (EcR). The THQ scaffold contains two chiral centers at the C-2 and C-4 positions, resulting in four stereoisomers. We have previously shown that the (2R,4S)-isomers are the most biologically active; however, the lack of a practical synthetic method for these isomers has hampered further structure-activity studies.
RESULTS: In this study, a chiral phosphoric acid-catalyzed Povarov reaction was employed to develop a facile asymmetric synthesis of THQs with a (2R,4S)-configuration, which allowed the preparation of a 40-compound library of enantiopure THQs. Evaluation of their binding affinity against Aedes albopictus EcR, followed by quantitative structure-activity relationship (QSAR) analyses, uncovered the physicochemical properties of THQs that are important for the ligand-receptor interaction. The most potent THQ derivative was twofold more active than the molting hormone, 20-hydroxyecdysone.
CONCLUSION: The QSAR results provide valuable information for the rational design of novel mosquito-specific ecdysone agonists.
© 2018 Society of Chemical Industry. © 2018 Society of Chemical Industry.

Entities:  

Keywords:  QSAR; asymmetric synthesis; ecdysone; mosquito; tetrahydroquinoline

Mesh:

Substances:

Year:  2018        PMID: 30070016     DOI: 10.1002/ps.5160

Source DB:  PubMed          Journal:  Pest Manag Sci        ISSN: 1526-498X            Impact factor:   4.845


  1 in total

1.  Receptor-binding affinity and larvicidal activity of tetrahydroquinoline-type ecdysone agonists against Aedes albopictus.

Authors:  Minori Ueno; Taiyo Yokoi; Yoshiaki Nakagawa; Hisashi Miyagawa
Journal:  J Pestic Sci       Date:  2021-02-20       Impact factor: 2.529

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.